Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving nucleic acid
Reexamination Certificate
2005-10-28
2009-12-15
Yu, Misook (Department: 1642)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving nucleic acid
Reexamination Certificate
active
07632643
ABSTRACT:
The present invention relates, in general, to a prostate-specific antigen, PCA3. In particular, the present invention relates to nucleic acid molecules coding for the PCA3 protein; purified PCA3 proteins and polypeptides; recombinant nucleic acid molecules; cells containing the recombinant nucleic acid molecules; antibodies having binding affinity specifically to PCA3 proteins and polypeptides; hybridomas containing the antibodies; nucleic acid probes for the detection of nucleic acids encoding PCA3 proteins; a method of detecting nucleic acids encoding PCA3 proteins or polypeptides in a sample; kits containing nucleic acid probes or antibodies; bioassays using the nucleic acid sequence, protein or antibodies of this invention to diagnose, assess or prognose a mammal afflicted with prostate cancer; therapeutic uses; and methods of preventing prostate cancer in an animal.
REFERENCES:
patent: 5466590 (1995-11-01), Sariaslani et al.
patent: 5773705 (1998-06-01), Vierstra et al.
patent: 6261562 (2001-07-01), Xu et al.
patent: 6262245 (2001-07-01), Xu et al.
patent: 6383739 (2002-05-01), Kurth et al.
patent: 6800746 (2004-10-01), Xu et al.
patent: 6897024 (2005-05-01), Bussemakers et al.
patent: 2002/0035244 (2002-03-01), Cohen et al.
patent: 2005/0158792 (2005-07-01), Bussemakers et al.
patent: 2005/0164223 (2005-07-01), Schalken et al.
patent: 2005/0282170 (2005-12-01), Fradet et al.
patent: O 160 228 (1985-11-01), None
patent: 0 520 794 (1992-12-01), None
patent: WO 94/09820 (1994-05-01), None
patent: WO 95/28498 (1995-10-01), None
patent: WO 96/14875 (1996-05-01), None
Bussemakers, M.J.G., et al., “DD3: A New Prostate Specific Marker, (Overexpressed in Prostatic Tumors),”Proc. Am. Cancer Res. Ann. Meeting 37:515, Abstract No. 3522 (1996).
Bussemakers, M.J.G., et al., “DD3: A New Prostate-Specific Marker, Strongly Overexpressed in Prostatic Tumors,”Urological Res. 25:76, Abstract No. 02.2 , Springer International (1997).
Bussemakers, M.J.G., et al., “DD3: A New Prostate-Specific Gene, Highly Overexpressed in Prostate Cancer,”Cancer Res. 59:5975-5979, American Association for Cancer Research (Dec. 1999).
Bussemakers, M.J.G., et al., “Identification of Genes Associated with Prostate Development,”Urological Res. 21:452, Abstract and Poster No. P42, Springer International (1993).
Bussemakers, M.J.G., et al., “Identification of Genes Associated with Prostate Development,” Abstract presented at the8thAnnual Spring Meeting of the Society for Basic Urologic Research, San Francisco, CA, 1994, 2 pages.
Bussemakers, M.J.G., et al., “Identification of DD3: A New Gene Overexpressed in Prostatic Tumors,”Urological Res. 23:253, Abstract No. 0 36, Springer International (1995).
Bussemakers, M.J.G., et al., “DD3: A New Prostate Specific Marker, Overexpressed in Prostatic Tumors,” Abstract presented at theFall Symposium of the Society for Basic Urologic Research, Chapel Hill, NC, 1995, p. 10.
Bussemakers, M.J.G., et al., “DD3: A New Prostate Specific Marker Overexpressed in Prostatic Tumors,” Presented at theBreast and Prostate Cancer: Basic Mechanisms Meeting, Taos, New Mexico, 1996, Abstract No. 102, p. 17.
Bussemakers, M.J.G., et al., “DD3: a new prostate specific marker, overexpressed in prostatic tumors,” Presented at the87thAnnual Meeting of the American Association for Cancer Research, Washington, DC, 1996, Abstract No. 3522, p. 515.
Bussemakers, M.J.G., et al., “DD3: A New Prostate Specific Marker, Overxpressed in Prostatic Tumors,” Presented at theDutch Association for Tumor Cell Biology Meeting, The Netherlands, 1996, 1 page.
Bowie, J.U., et al., “Deciphering the message in protein sequences: tolerance to amino acid substitutions,”Science 247:1306-1310, American Association for the Advancement of Science (1990).
Burgess, W.H., et al., “Possible dissociation of the heparin-binding and mitogenic activities of heparin-binding (acidic fibroblast) growth factor-1 from its receptor-binding activities by site-directed mutagenesis of a single lysine residue,”J. Cell. Biol. 111:2129-2138, Rockefeller University Press (1990).
Freidmann, T., “Overcoming the obstacles the gene therapy,”Sci. Am. 276:96-101, Scientific American (Jun. 1997).
Gandini, O., et al., “Is DD3 a New Prostate-Specific Gene?,”Anticancer Res. 23:305-308, J.G. Delinassios, Anticancer Research (Jan.-Feb. 2003).
Houdebine, L.M., “Production of pharmaceutical proteins from transgenic animals,”J. Biochem. 34:269-287, Oxford University Press (1994).
Lazar, E., et al.., “Transforming growth factor alpha: mutation of aspartic acid 47 and leucine 48 results in different biological activities,”Mol. Cell Biol. 8:1247-1252, American Society for Microbiology (1988).
Merriam-Webster Online Dictionary, available online at www.m-w.com, accessed Sep. 30, 2003.
Report of Invention entitled: “DD3: A Novel Prostate-Specific Gene, overexpressed in prostate adenocarcinomas,” dated Oct. 17, 1996, 2 pages.
Rubanyi, G.M., “The future of human gene therapy.,”Mol. Aspects Med. 22:113-142, Elsevier Science (Jun. 2001).
Tamimi, Y., et al., “DiagnoGene PCA3 reliable NASBA based reagents for detecting PCA3 mRNA, a recently described prostate marker,”Proc. Am. Assoc. Cancer Res. 39:234, Poster Abstract (1998).
U.S. Appl. No. 09/675,650, Busse et al., filed Sep. 29, 2000 (Not Published).
Voet, D., et al., Biochemistry, John Wiley & Sons, Inc., pp. 893-900 (1990).
Verma, I.M. and Somia, N., “Gene therapy—promises, problems and prospects.,”Nature 389:239-242, Nature Publishing Group (Sep. 1997).
Lathe, R., “Synthetic Oligonucleotide Probes Deduced from Amino Acid Sequence Data Theoretical and Practical Considerations,”J. Mol. Biol. 183, 1-12 (1985).
Bussemakers Marion J. G.
Isaacs William B.
Goudreau Gage Dubuc
Stichting Katholieke Universiteit, More Particularly the Univers
The Johns Hopkins University
Yu Misook
LandOfFree
PCA3, PCA3 genes, and methods of use does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with PCA3, PCA3 genes, and methods of use, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and PCA3, PCA3 genes, and methods of use will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4058962